Issue
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
Safe and probably safe drugs in acute hepatic porphyria
Corresponding Author(s) : U Stölzel
u.stoelzel@skc.de
Cellular and Molecular Biology,
Vol. 55 No. 2: Porphyrias and associated pathologies. Biochemistry and molecular biology Part 2
Abstract
Acute porphyrias are caused by enzyme defects along the heme synthesis pathway. Patients usually present with abdominal pain, impaired intestinal motility, neurological and psychiatric symptoms, hypertension, tachycardia, hyponatriemia and reddish urine. This article gives an overview over drugs that are recommended in patients with acute hepatic porphyrias and represents a compilation of four so far existing lists.
Keywords
Acute Porphyria
medication
treatment of Acute Porphyria
heme
heme arginate|.
Stölzel, U., Brosche, C., Koszka, C., Stauch, T., Teubner, A., & Doss, M. O. (2009). Safe and probably safe drugs in acute hepatic porphyria. Cellular and Molecular Biology, 55(2), 147–151. Retrieved from https://mail.cellmolbiol.org/index.php/CMB/article/view/1098
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX